PT-141 (Bremelanotide) (10mg) – Premium Research Peptide for Melanocortin Studies
Welcome to Liaocheng Yixin Company, your trusted source for premium pt-141 bremelanotide 10mg for research. As a specialized peptide synthesis manufacturer operating from our facility at No. 9 Lushan Road, Dongcheng Street, Liaocheng Economic and Technological Development Zone, Shandong Province, we provide high-quality research compounds for the global scientific community.
PT-141, also known as Bremelanotide, is a synthetic cyclic peptide analog of alpha-melanocyte-stimulating hormone (α-MSH) that functions as an agonist at melanocortin receptors . This centrally acting peptide is one of the most extensively studied melanocortin compounds in neuroscience research, with a well-characterized mechanism of action and a mature research dossier . Our pt-141 bremelanotide 10mg for research offers investigators a reliable, high-purity compound for neuroscience and behavioral research.
What is PT-141 (Bremelanotide)?
PT-141 (Bremelanotide, CAS: 189691-06-3) is a synthetic cyclic peptide analog of α-MSH that exhibits agonist activity at melanocortin receptors, with primary affinity for MC4R and MC3R .
Key identifiers:
-
CAS Number: 189691-06-3
-
Molecular Formula: C50H68N14O10
-
Molecular Weight: 1025.16 g/mol
-
Sequence: Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys)-OH (Acetate Salt)
-
Synonyms: Bremelanotide, PT-141, Vyleesi®
-
Purity: ≥99% verified by HPLC
Mechanism of Action in Research
PT-141 exerts its effects through selective activation of melanocortin receptors expressed primarily in the central nervous system :
MC4R and MC3R Agonism
PT-141 demonstrates high affinity for melanocortin receptors with the following binding affinities :
-
MC4 receptor: pKi 9.6 (Ki = 2.5 × 10⁻¹⁰ M) – strongest affinity
-
MC1 receptor: pKi 8.2 (Ki = 6.4 × 10⁻⁹ M)
-
MC5 receptor: pKi 7.8 (Ki = 1.7 × 10⁻⁸ M)
-
MC3 receptor: pKi 7.3 (Ki = 5.3 × 10⁻⁸ M)
MC4R receptors are extensively expressed in hypothalamic nuclei—key integrative centers for investigating neural pathways underlying motivational and behavioral responses .
Central Nervous System Mechanism
Unlike peripheral-acting compounds, PT-141 acts centrally on melanocortin receptors in the brain, distinguishing it from vascular-targeting research agents . This distinction makes PT-141 valuable for research exploring the neural pathways underlying motivation, behavior, and arousal.
Pharmacokinetic Profile in Research
PT-141 is administered via subcutaneous injection with the following pharmacokinetic properties :
| Parameter | Value |
|---|---|
| Bioavailability | ~100% |
| Time to Peak (Tmax) | ~1.0 hour (range: 0.5-1.0 hours) |
| Peak Concentration (Cmax) | 72.8 ng/mL |
| Plasma Protein Binding | 21% |
| Elimination Half-Life (t1/2) | ~2.7 hours (range: 1.9-4.0 hours) |
| Excretion | 64.8% in urine, 22.8% in feces |
Scientific Research Applications
PT-141 has been extensively studied across multiple research domains:
Sexual Behavior Research
A key preclinical model utilized ovariectomized female rats to assess appetitive sexual behaviors, which are considered analogous to motivational components in humans . Key findings demonstrated that PT-141 significantly and selectively increased appetitive sexual behaviors, such as solicitations, without affecting reflexive responses. This selective effect provided evidence that PT-141 acts on the motivational components of behavioral response .
Men’s Health Research
A study from a sexual medicine clinic evaluated PT-141 in men with sexual dysfunction over a 46-month period . Results showed:
-
75% reported increased satisfaction with lovemaking
-
88% reported easier vaginal insertion
-
80% reported being more at ease with initiating sexual activity
-
72% felt overall sexual function improved
Phase 2 Clinical Research
A randomized, double-blind, placebo-controlled Phase 2b trial (NCT01382719) evaluated PT-141 in premenopausal women :
| Endpoint (Change from Baseline) | Placebo | PT-141 (1.25/1.75 mg pooled) | P-value |
|---|---|---|---|
| Satisfying Sexual Events / Month | +0.2 | +0.7 | 0.0180 |
Phase 3 RECONNECT Research
The RECONNECT program comprised two identical Phase 3 trials evaluating PT-141 in women . The integrated analysis showed:
-
FSFI-Desire Domain: +0.35 change from baseline (P < .001)
-
FSDS-DAO Item 13: -0.33 change (P < .001)
-
Most common adverse events: nausea (40.0%), flushing (20.3%), headache (11.3%)
Why Choose Liaocheng Yixin Company?
When sourcing pt-141 bremelanotide 10mg for research, quality and reliability are paramount. Here’s why researchers trust us:
Manufacturer-Direct Quality
We are a legitimate, licensed peptide synthesis company with a physical headquarters in Shandong Province, China. Our facility maintains strict quality control standards.
Verified Purity Standards
Every batch undergoes rigorous testing using HPLC analysis. Research-grade PT-141 typically demonstrates purity levels exceeding 97-99% . Certificates of Analysis are available upon request.
Research-Grade Specifications
-
Purity: ≥99% verified by HPLC
-
Appearance: White lyophilized powder
-
Solubility: Soluble in water (reconstitute in sterile water ≥100 µg/ml)
-
Storage: Store powder at -20°C in a sealed container, protected from light and moisture
-
Form: Lyophilized powder for research use
Quality Assurance & Testing
Every batch undergoes comprehensive quality control:
-
Synthesis by experienced chemists using solid-phase peptide synthesis
-
Purification via preparative HPLC
-
Analysis using HPLC for purity verification
-
Mass Spectrometry for molecular weight confirmation
-
Packaged in sterile conditions for research use
When you need premium pt-141 bremelanotide 10mg for research for your neuroscience or behavioral studies, choose a manufacturer that prioritizes quality, transparency, and reliability. Liaocheng Yixin Company combines expert peptide synthesis capabilities with rigorous quality control to deliver research materials you can trust.




Reviews
There are no reviews yet.